Pain, Nausea, Vomiting
Conditions
Keywords
Pain, Nausea, Vomiting
Brief summary
The purpose of CLCT-006, a multi-center open-label study, is to evaluate the safety of CL-108 (hydrocodone 7.5 mg/APAP 325 mg, promethazine 12.5 mg) for the treatment of moderate to severe acute pain (flare) associated with osteoarthritis of the knee or hip under actual conditions of use.
Detailed description
The purpose of CLCT-006, a multi-center open-label study, is to evaluate the safety of CL-108 (hydrocodone 7.5 mg/APAP 325 mg, promethazine 12.5 mg) for the treatment of moderate to severe acute pain (flare) associated with osteoarthritis of the knee or hip under actual conditions of use. The study will also endeavor to determine * the physicians' global evaluation of CL-108 as a treatment for moderate to severe acute pain associated with osteoarthritis of the knee or hip * the patients' global impression of change in pain after treatment of moderate to severe acute pain associated with osteoarthritis of the knee or hip * any change in the patient's quality of life after treatment of moderate to severe acute pain associated with osteoarthritis of the knee or hip * the percentage change in pain intensity after treatment of moderate to severe acute pain associated with osteoarthritis of the knee or hip
Interventions
DRUGCL-108
Sponsors
Charleston Laboratories, Inc
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Informed consent * Signed consent obtained at screening prior to any procedures being performed. Gender * Male or non-pregnant and non-lactating female. A female of child-bearing potential is eligible to participate in this study if she has a negative urine pregnancy test and is post-menopausal or using an acceptable method of birth control (i.e., hormonal, transdermal, or implanted contraceptives, intra-uterine device, diaphragm, condom, abstinence, or surgical sterilization) Age * At least 18 years of age Diagnosis of OA * Clinical diagnosis of osteoarthritis of the hip and/or knee (signal joints) based on history and physical findings Confirmation of OA * Radiographic evidence of OA of the knee or hip (e.g., joint space narrowing, K-L grades 1-4). \[Any X-ray finding or report of an X-ray finding at any time that is indicative of OA of the knee or hip confirms the diagnosis of OA.\] Treatment of OA * Inadequate or unsatisfactory treatment with an NSAID for OA of the knee or hip with no previous use of an opioid for OA (i.e., need for step up to opioid treatment). Flare of OA * Complaint of acute pain in the knee or hip (i.e., flare of osteoarthritis of the knee or hip) Duration of Acute Pain * Pain in the signal joint(s) with onset ≤ 14 days Pain Severity * Baseline PIS score must be ≥ moderate Alcohol Intake * Willing to limit alcohol intake to ≤ 2 drinks per day during the study (i.e., from Screening Visit 1 through Follow-Up Visit 3) Diary Completion * Be willing and able to record effectiveness, tolerability, and drug utilization information in the In-Clinic and Outpatient Diaries.
Exclusion criteria
Medical Condition * Presence of a serious uncontrolled medical condition (e.g., poorly controlled hypertension or diabetes) Confounding Diseases * Presence of other major joint or bone disease (e.g., gout, inflammatory arthritis, Paget's disease), chronic pain syndrome, or fibromyalgia Surgery * Patients who have had surgery on the affected joint within the past 6 months, subjects with a prosthesis at the index joint, patients possibly requiring knee or hip arthroplasty or other surgical procedure on the index joint within 3 months following screening Drug Allergy * History of hypersensitivity to an opioid drug, promethazine, acetaminophen, or NSAID (such as ibuprofen) or history of a dystonic/dyskinetic reaction to prior antiemetic or anti-psychotic medication Confounding and Contraindicated Drugs * Use within 24 hours of Visit 2 of any analgesic (in particular, opioid), anti-emetic, glucosamine, chondroitin sulfate, or any drug contraindicated with hydrocodone, acetaminophen, or promethazine. Use within 4 months of Visit 2 of any intra-articular or oral corticosteroid or hyaluronic acid. Investigational Drug Use * Use of any investigational drug within the past 30 days Participated in Study * Previous participation in this study Pregnancy, Lactation * Women who are pregnant or breast-feeding Participant Relationship * Employee of the Principal Investigator, Sub-investigators or Charleston Laboratories or relative of an employee who is directly involved in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The safety of CL-108 will be evaluated and assessed by questionnaire, when used, for the treatment of moderate to severe acute pain associated with osteoarthritis of the knee or hip. | 24 hours |
Secondary
| Measure | Time frame |
|---|---|
| An assessment of the study medication will be provided as a treatment for osteoarthritis on the Physician's Global Evaluation (PGE) utilizing a poor to excellent scale | 24 hours |
| The change in arthritic pain since taking study medication over a specific period will be assessed on the Patient Global Impression of Change scale (PGIC) | 24 hours |
| Patients will complete a standard QOL questionnaire, comprising five dimensions of health-related quality of life (mobility, self-care, usual activities, pain/discomfort, and anxiety/ depression). | 24 hours |
Countries
United States
Outcome results
None listed